published in The Lancet Neurology, the perceived risk from restarting antiplatelet therapy after intracerebral haemorrhage in patients with cerebral microbleeds has been substantially overestimated on the basis of observational data. Use of antiplatelet therapy in patients with intracerebral haemorrhage is common, 3 a conservative estimate is one in four patients, so more certainty in making decisions regarding restarting such therapy is highly relevant.
The RESTART trial, 4 which is published in The Lancet, randomly assigned 537 survivors of intracerebral haemorrhage that occurred while taking antithrombotic therapy to start or avoid antiplatelet therapy. The investi gators reported no significant differences in risk of recurrent intracerebral haemorrhage but a reduced risk, albeit not reaching statistical signifi cance, of both haemor rhagic and ischaemic stroke was observed consistently in subgroups in patients allocated to start anti platelet therapy. 4 The neuroimaging substudy 2 of the RESTART trial, published in The Lancet Neurology, focused on the 254 patients with MRI performed before randomisation. By contrast with previous observational data, there were no indications that starting antiplatelet therapy increased risk of recurrent intracerebral haemorrhage in patients with cerebral microbleeds or superficial siderosis. The number of microbleeds did not seem to affect risk of recurrent intracerebral haemorrhage.
RESTART is the first randomised trial to address this subject; until now, data were based on observational hospital cohorts that suggested excess risk of recurrent intracerebral haemorrhage from reintroduction of antiplatelets, with the highest risk in patients with cerebral microbleeds. 5 Un certainty remains in relation to the precision of these findings. RESTART was under powered: a sample size of 2200 is suggested by the investigators as needed for a potentially conclusive study. However, findings were con sistent across prespecified subgroups. Selection bias towards small haematomas was present: median intracerebral haemorrhage volume was 3·7 mL in the intervention group and 4·3 mL in the control group, and few participants had high numbers of microbleeds. There was a predominance of men in the MRI substudy and entire cohort. Also, all MRI field strengths were accepted and gradient-recalled echo was used for bleeding detection, which most likely led to lower detection rates of cerebral microbleeds than what would have been the case if based on high field strengths or susceptibility weighted imaging, or both. 6 Consequently, the results could be substantially different in an adequately powered trial and therefore the external validity of the results of the current substudy in relation to the overall intracerebral haemor rhage population is unclear-for example, these results can not be directly extrapolated to patients with larger haematoma volumes or large numbers of microbleeds. However, the investigators have succeeded in recruiting a high-risk population; the proportion of recurrent intracerebral haem orrhage was 4·9% in the start antiplatelet therapy group versus 9·1% in the control group during an average follow-up of 2 years. 2 Furthermore, con sideration of reinitiation of antiplatelet therapy is most pertinent in patients with small haematomas and good outcome.
These data are indeed surprising because most stroke clinicians would have expected that presence of cerebral microbleeds heralds higher risk of recurrent intracerebral haemorrhage on starting antiplatelet therapy, because the higher risk of intracerebral haem orrhage in patients with microbleeds has been well documented, 7 and observational data support further increase in risk with use of antithrombotic drugs. 5, 8 That antiplatelet therapy increases risk of intracerebral haemorrhage overall and that patients after intracerebral haemorrhage have high risk of recurrence do not necessarily imply that antiplatelet therapy will increase risk of intracerebral haemorrhage in this patient population. Furthermore, imaging findings such as the presence of microbleeds can often arouse concern, which can be worrying even in the absence of intracerebral haemorrhage-but possibly more for the clinician than for the patient's prognosis. These findings underline that our pathophysiological understanding remains incomplete and we should not rely on observational data, but always aim for randomised controlled data. More data are certainly needed in this field, including data on specific antiplatelet drugs and specific combinations of antiplatelet drugs that are frequently used-eg, standard regimens for acute coronary syndrome. Data from ran domised controlled trials are also needed for oral anticoagulants, for which a parallel discussion is ongoing.
My clinical interpretation of these results is that physicians can be less restrictive in prescribing anti plate lets to patients with minor intracerebral haemor rhage. Decisions cannot be made on the basis of MRI findings such as cerebral microbleeds; according to these data, there is no excess risk attributed to the antiplatelet intervention in this population, so the focus of a therapeutic decision should rest not on the reasons to prescribe antiplatelets, but on the reasons not to prescribe them. However, the best evidence remains to be from randomised trials when available: RESTART-Fr (NCT02966119) and STATICH (NCT03186729) are ongoing and might settle any remaining uncertainty.
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